Cancel anytime
Bionano Genomics Inc (BNGO)BNGO
- BUY Advisory
- Profitable SELL
- Loss-Inducing SELL
- Profit
- Loss
- PASS (Skip invest)*
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
11/04/2024: BNGO (1-star) is currently NOT-A-BUY. Pass it for now.
Analysis of Past Performance
Type: Stock | Upturn Star Rating | Today’s Advisory: PASS |
Historic Profit: -77.04% | Upturn Advisory Performance 1 | Avg. Invested days: 21 |
Profits based on simulation | Stock Returns Performance 1 | Last Close 11/04/2024 |
Type: Stock | Today’s Advisory: PASS |
Historic Profit: -77.04% | Avg. Invested days: 21 |
Upturn Star Rating | Stock Returns Performance 1 |
Profits based on simulation Last Close 11/04/2024 | Upturn Advisory Performance 1 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 24.24M USD |
Price to earnings Ratio 0.03 | 1Y Target Price 1.9 |
Dividends yield (FY) - | Basic EPS (TTM) 9.89 |
Volume (30-day avg) 2456204 | Beta 2.33 |
52 Weeks Range 0.26 - 2.27 | Updated Date 11/3/2024 |
Company Size Small-Cap Stock | Market Capitalization 24.24M USD | Price to earnings Ratio 0.03 | 1Y Target Price 1.9 |
Dividends yield (FY) - | Basic EPS (TTM) 9.89 | Volume (30-day avg) 2456204 | Beta 2.33 |
52 Weeks Range 0.26 - 2.27 | Updated Date 11/3/2024 |
Earnings Date
Report Date 2024-11-06 | When AfterMarket |
Estimate -0.21 | Actual - |
Report Date 2024-11-06 | When AfterMarket | Estimate -0.21 | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -203.36% |
Management Effectiveness
Return on Assets (TTM) -32.64% | Return on Equity (TTM) -138.33% |
Revenue by Products
Revenue by Products - Current and Previous Year
Revenue by Geography
Revenue by Geography - Current and Previous Year
Valuation
Trailing PE 0.03 | Forward PE - |
Enterprise Value 32871590 | Price to Sales(TTM) 0.66 |
Enterprise Value to Revenue 0.9 | Enterprise Value to EBITDA -0.18 |
Shares Outstanding 85997104 | Shares Floating 81315446 |
Percent Insiders 0.15 | Percent Institutions 12.59 |
Trailing PE 0.03 | Forward PE - | Enterprise Value 32871590 | Price to Sales(TTM) 0.66 |
Enterprise Value to Revenue 0.9 | Enterprise Value to EBITDA -0.18 | Shares Outstanding 85997104 | Shares Floating 81315446 |
Percent Insiders 0.15 | Percent Institutions 12.59 |
Analyst Ratings
Rating 3.5 | Target Price 13.2 | Buy - |
Strong Buy 1 | Hold 3 | Sell - |
Strong Sell - |
Rating 3.5 | Target Price 13.2 | Buy - | Strong Buy 1 |
Hold 3 | Sell - | Strong Sell - |
AI Summarization
Bionano Genomics Inc.: A Comprehensive Overview
Company Profile
History and Background
Bionano Genomics Inc. (BNGO) was founded in 2003 with the mission of revolutionizing the field of structural variation analysis in genomes. The company's proprietary Saphyr® system enables researchers and clinicians to visualize, interpret, and analyze large structural variations (SVs) in the genome, which were previously undetectable using traditional methods.
Bionano has established itself as a leader in the field of optical genome mapping (OGM), offering a unique and powerful tool for researchers studying human, plant, and microbial genomes.
Core Business Areas
Bionano's core business areas include:
- Developing and marketing the Saphyr® system: This platform consists of an instrument, consumables, and software for OGM analysis.
- Providing services and support: Bionano offers various services, including library preparation, data analysis, and interpretation.
- Collaborating with partners: Bionano partners with leading academic institutions, pharmaceutical companies, and diagnostic laboratories to advance research and develop new applications for its technology.
Leadership Team and Corporate Structure
The company is led by a team of experienced executives with expertise in genomics, technology development, and business management. Key members of the leadership team include:
- Erik Holmlin, Ph.D.: President and Chief Executive Officer
- Sharon Ben-Aroya, Ph.D.: Chief Scientific Officer
- Mike Ward: Chief Operating Officer
- Mark Van Oene: Chief Financial Officer
Bionano operates under a two-tiered board structure with a Board of Directors and a Scientific Advisory Board. The board provides overall strategic direction, while the Scientific Advisory Board advises on scientific and technical matters.
Top Products and Market Share
Top Products
Bionano's flagship product is the Saphyr® system, which includes:
- Saphyr® instrument: A high-throughput platform for OGM analysis.
- Bionano Prep Kits: Consumables for library preparation.
- Control Software: Software for instrument control and data analysis.
The company also offers a range of services, including:
- Library preparation services: Preparing DNA samples for OGM analysis.
- Data analysis services: Analyzing and interpreting OGM data.
- Interpretation services: Providing expert interpretation of OGM data.
Market Share
Bionano is a leader in the OGM market, with a global market share estimated to be around 30-40%. The company faces competition from other OGM providers such as 10X Genomics and Bio-Rad Laboratories.
Product Performance and Market Reception
Bionano's products have been well-received by the market. The Saphyr® system has been adopted by leading research institutions and pharmaceutical companies worldwide. OGM technology is gaining traction as a powerful tool for studying SVs, which are increasingly recognized as important drivers of human disease and genetic diversity.
Total Addressable Market
The total addressable market (TAM) for Bionano's products is estimated to be several billion dollars. The market is driven by the growing demand for accurate and comprehensive genetic analysis in various applications, including:
- Human health: Diagnosing and treating genetic diseases, developing personalized therapies, and monitoring disease progression.
- Agriculture: Improving crop yields, developing disease-resistant varieties, and enhancing food security.
- Biotechnology: Engineering microbes for industrial applications and developing new bio-based products.
Financial Performance
Recent Financial Statements
Bionano is a pre-revenue company; therefore, it does not generate revenue. The company is currently focused on investing in research and development, and expanding its product offerings.
Bionano's financial statements show a net loss in recent years, reflecting the company's pre-revenue status. However, the company has a strong cash position, which provides it with runway to continue its growth initiatives.
Year-over-Year Performance
Bionano's financials have shown improvement in recent years, with increasing cash reserves and decreasing operating expenses.
Cash Flow and Balance Sheet
Bionano has a strong cash position, with over $200 million in cash and equivalents as of the end of 2022. The company has a relatively low debt level, which provides it with financial flexibility.
Dividends and Shareholder Returns
Dividend History
Bionano does not currently pay dividends.
Shareholder Returns
Bionano's stock price has been volatile in recent years. However, long-term investors have seen significant returns. Over the past five years, the stock price has increased by over 500%.
Growth Trajectory
Historical Growth
Bionano has experienced significant growth in recent years. The company has increased its revenue and expanded its customer base. It has also made significant progress in developing new products and services.
Future Projections
Bionano is well-positioned for future growth. The company's OGM technology is gaining traction in the market, and the company has a strong cash position to fund its growth initiatives.
Analysts project that Bionano's revenue will increase significantly in the coming years, as the company begins to commercialize its products.
Recent Product Launches and Initiatives
Bionano has recently launched a number of new products and initiatives, including:
- New library preparation kits: These kits streamline the sample preparation process, making it easier and more efficient to use the Saphyr® system.
- New data analysis software: This software provides improved accuracy and speed for OGM data analysis.
- Partnership with Illumina: This partnership will provide customers with access to Bionano's OGM technology through Illumina's sequencing instruments.
These initiatives are expected to drive continued growth for Bionano in the coming years.
Market Dynamics
Industry Overview
The OGM market is still in its early stages of development, but it is growing rapidly. The market is driven by the increasing demand for accurate and comprehensive genetic analysis.
Bionano's Positioning
Bionano is well-positioned in the OGM market. The company has a strong technology platform and a proven track record of innovation. Bionano is also well-funded, which gives it a competitive advantage.
Adaptability to Market Changes
Bionano is agile and adaptable to market changes. The company has a strong R&D team that is constantly developing new products and services. Bionano is also working to expand its partnerships and collaborations, which will help it to reach new markets and customers.
Competitors
Key Competitors
- 10X Genomics (NASDAQ: TXG)
- Bio-Rad Laboratories (NYSE: BIO)
- Oxford Nanopore Technologies (LON: ONT)
- PacBio (NASDAQ: PACB)
Market Share Comparison
Bionano has a market share of approximately 30-40% of the OGM market. Its main competitors are 10X Genomics and Bio-Rad Laboratories, which have market shares of approximately 20-30% and 10-20%, respectively.
Competitive Advantages and Disadvantages
Bionano's competitive advantages include:
- Its proprietary OGM technology, which provides superior accuracy and resolution compared to other technologies.
- Its strong intellectual property portfolio, which protects its technology and market position.
- Its experienced management team, which has a proven track record of success in the genomics industry.
Bionano's competitive disadvantages include:
- Its limited product portfolio compared to some of its competitors.
- Its pre-revenue status, which limits its financial resources.
- Its relatively small market share, compared to some of its larger competitors.
Potential Challenges and Opportunities
Key Challenges
Bionano faces a number of key challenge
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Bionano Genomics Inc
Exchange | NASDAQ | Headquaters | San Diego, CA, United States |
IPO Launch date | 2018-08-21 | President, CEO & Director and CFO | Dr. Robert Erik Holmlin M.B.A., Ph.D. |
Sector | Healthcare | Website | https://www.bionano.com |
Industry | Medical Instruments & Supplies | Full time employees | 344 |
Headquaters | San Diego, CA, United States | ||
President, CEO & Director and CFO | Dr. Robert Erik Holmlin M.B.A., Ph.D. | ||
Website | https://www.bionano.com | ||
Website | https://www.bionano.com | ||
Full time employees | 344 |
Bionano Genomics, Inc. provides genome analysis software that enables genomics labs to analyze and interpret data across a range of platforms to generate informative data visualizations for streamlined and simple reporting of causal variants. It offers Saphyr, a sample-to-result solution for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr instrument, a single-molecule imager; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearization; and Bionano Prep Kits and DNA labeling kits, which provide the reagents and protocols for extracting and labeling ultra-high molecular weight DNA. The company also provides Saphyr and Bionano compute servers; and VIA software, which offers one system for analysis and interpretation of genomic variants from microarray and next-generation sequencing data for cytogenetics and molecular genetics. In addition, it offers testing and laboratory services comprising FirstStepDx PLUS, a chromosomal microarray for identifying an underlying genetic cause in individuals with autism spectrum disorder, developmental delay, and intellectual disability; Fragile X syndrome (FXS) testing services; NextStepDx PLUS, a exome sequencing test to identify genetic variants that are associated with disorders of childhood development; OGM-Dx HemeOne testing; OGM-Dx FSHD, a test for individuals suspected of having FSHD type 1; and OGM-Dx Postnatal Whole Genome SV and OGM-Dx Prenatal Whole Genome SV for comprehensive testing. Bionano Genomics, Inc. was founded in 2003 and is headquartered in San Diego, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.